Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Oncaspar
DRUG
3 trials
Sponsors
medac GmbH
, Dana-Farber Cancer Institute
Conditions
Acute Lymphoblastic Leukaemia
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia (ALL)
Leukemia
Lymphoblastic Lymphoma
Philadelphia Chromosome-Negative Lymphoblastic Leukemia
Phase 1
Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia
Terminated
NCT01251809
medac GmbH
Acute Lymphoblastic Leukaemia
Start: 2011-01-31
End: 2013-05-31
Target: 56
Updated: 2013-05-20
Phase 2
SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
Active, not recruiting
NCT01574274
Dana-Farber Cancer Institute
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Start: 2012-06-01
End: 2027-07-01
Updated: 2026-07-28
ALL Backbone in AYAs
Recruiting
NCT07227584
Dana-Farber Cancer Institute
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Leukemia +1
Start: 2026-04-03
End: 2035-07-31
Target: 67
Updated: 2026-08-17
Related Papers
Feasibility of serial neurocognitive assessment using Cogstate during and after therapy for childhood leukemia.
2023-01-10
4 citations
Vitamin A and association with asparaginase-associated pancreatitis in children with acute lymphocytic leukemia.
Journal of Clinical Oncology
2022-06-01
2 citations
Identification of prognostic factors in childhood T‐cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05‐001 and 11‐001
Pediatric Blood & Cancer
2020-10-07
56 citations
Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma: Results of DFCI 11-001.
Journal of Clinical Oncology
2019-05-20
8 citations